Skip to content
Search

Latest Stories

Top Stories

Bill of the month: Limiting Chinese influence in the biotech sector

WuXi AppTec building

The BIOSECURE Act takes direct aim at five Chinese companies, including WuXi AppTec.

CFOTO/Future Publishing via Getty Images

Rogers is the “data wrangler” at BillTrack50. He previously worked on policy in several government departments.

This month IssueVoter and BillTrack50 take a look at the BIOSECURE Act, a significant escalation in efforts to restrict Chinese influence in America's biotechnology sector.

The bipartisan legislation, passed by the House of Representatives in September and spearheaded by Reps. Brad Wenstrup (R-Ohio) and Raja Krishnamoorthi (D-Ill.), aims to protect American patient data and prevent federal funds from flowing to biotechnology companies deemed to pose national security risks.


Key Provisions

At its core, the BIOSECURE Act seeks to create a firewall between federal agencies and certain biotechnology companies. Under the legislation, federal agencies would be barred from contracting with designated "biotechnology companies of concern" or providing grants and loans to entities that use their services.

This prohibition extends to organizations that maintain contracts with these companies, creating a ripple effect throughout the biotechnology supply chain.

The bill takes direct aim at five Chinese companies: BGI, MGI, Complete Genomics, WuXi AppTec,and WuXi Biologics. Beyond these specific designations, it establishes a framework for identifying additional companies as security risks, particularly those controlled by "foreign adversaries" including China, Russia, North Korea, Iran and Cuba.

Weaponizing Our Genome

Supporters of the BIOSECURE Act, with Wenstrup at the forefront, paint a concerning picture of vulnerable national security and compromised patient privacy.

Sign up for The Fulcrum newsletter

As Krishnamoorthi dramatically frames the issue: "As Americans have their blood drawn or take other medical tests each day, few have any idea that their personal genetic information could be going to biotech companies controlled by the Chinese Communist Party and other adversaries that would weaponize our own genomes against us."

The military connections between Chinese biotech firms and the People's Liberation Army have raised additional red flags. These relationships reportedly extend beyond mere collaboration to include joint research projects and shared genetic collection sites. The fact that WuXi AppTec derives over 60 percent of its revenue from the U.S. market has intensified concerns about American dependency on potentially compromised supply chains.

Perhaps most alarming to supporters is China's legal framework requiring companies to share data with the government upon request. This mandate creates a direct pipeline for sensitive genetic information about American citizens to flow into the hands of Chinese authorities.

Opposition and Concerns

Yet the legislation has drawn significant criticism, even from unexpected quarters. Rep. Jim McGovern (D-Mass.), known for his tough stance on China, has emerged as a prominent critic. In his forceful opposition to the bill, McGovern argues: "Naming specific companies will create a 'whack-a-mole' situation where entities can change their name and reincorporate to evade sanctions. ... [I]t's totally wrong to call out specific companies without any formal investigation or interagency process —that might be how they do things in the PRC, but this is the United States of America where we ought to have a thorough, independent investigation."

Company Responses

Health care technology executives have added their voices to the chorus of concern. At the Clinical Trial Supply West Coast 2024 conference, Umar Hayat of Gladius Therapeutics offered a stark warning: "This seems more like politics rather than about a security threat. ... [I]f you want to play politics, play politics in other industries like automotive, electronics or telecommunications. Don't play politics in health care where so many people are in dire need. Let science evolve and advance — wherever it comes from."

BGI has mounted a vigorous defense against the allegations, emphasizing that it maintains no direct patient services in the United States and therefore has no access to Americans' personal data. The company has clarified that its Covid-19 PCR testing analyzes only viral RNA, not patient DNA, and stressed its status as a privately owned entity independent from Chinese government control. BGI likens its gene bank operations to those of U.S. national laboratories, suggesting that fears about its activities may be overblown.

Broader Implications

The BIOSECURE Act represents more than a simple regulatory change; it signals a fundamental shift in how the United States approaches biotechnology in the context of national security. This transformation raises complex questions about the future of international scientific collaboration at a time when global cooperation has proven crucial for addressing health challenges.

The legislation could trigger a significant reorganization of pharmaceutical supply chains, with countries like Ireland and India potentially emerging as alternative manufacturing locations. However, this restructuring comes with its own set of challenges and uncertainties.

Innovation in the biotechnology sector could face headwinds as restrictions on collaboration with Chinese firms affect the development pipeline for new treatments. The legislation also adds another layer of complexity to U.S.-China relations, potentially complicating ongoing dialogue in other areas.

Looking Ahead

As the BIOSECURE Act moves to the Senate with strong bipartisan support, its passage could mark a watershed moment in U.S. biotechnology policy. Policymakers face the delicate task of balancing legitimate national security concerns with the benefits of international scientific collaboration and market competition.

The debate over this legislation reflects deeper questions facing the biotechnology sector about the relationship between national security and scientific progress. How nations protect sensitive genetic data while maintaining scientific openness, and the role of national security considerations in health care innovation, will likely shape the future of global biotechnology development for years to come.

The answers to these questions will determine not just the future of U.S.-China relations in biotechnology, but the pace and direction of medical innovation in an increasingly interconnected world.

Read More

A Community Response to Disabled Gun Violence Survivors

A Community Response to Disabled Gun Violence Survivors

“What did you see once you got shot?” That might not be one of the first things victims of gun violence are asked, but it was the first question Access Living asked in a survey used to address and assess the many difficulties survivors of gun violence faced.

The nation’s gun violence crisis continues to be a significant threat to people’s lives, as it has claimed over 10,000 lives in the United States every year for the past 10 years, according to Gun Violence Archive. Only three months into 2025, there have been over 100 shootings reported in Chicago, and this will probably continue to rise, as in the country in 2023, on average, 118 people died of gun violence a day. According to the National Institute for Health Care Management Foundation, for every person who dies due to gun violence, more than two survive, usually with significant lifelong physical injuries that they have to learn to live with, along with the mental trauma of the incident.

Keep ReadingShow less
Improving Infrastructure In Washington To Benefit Both People and Nature

The 50: Washington

Improving Infrastructure In Washington To Benefit Both People and Nature

The 50is a four-year multimedia project in which the Fulcrum visits different communities across all 50 states to learn what motivated them to vote in the 2024 presidential election and see how the Donald Trump administration is meeting those concerns and hopes.

Washington State has historically fluctuated between Republican and Democratic preferences. While it was considered a Republican-leaning swing state until the 1980s, the political landscape shifted significantly in the following decades. Since 1988, the Democratic Party has won every presidential election in Washington, consistently achieving victory by double-digit margins since 2008.

Keep ReadingShow less
House passes 1,100-page spending and tax bill, raising debt by up to $4 trillion

US Capitol

Roberto Schmidt/AFP via Getty Images

House passes 1,100-page spending and tax bill, raising debt by up to $4 trillion

Early Thursday morning the House passed H.R. 1: One Big Beautiful Bill Act — yes, that’s it’s official title — a 1,100+ page bill with large cuts to both spending and taxes. We know the big picture but little about the details because it hasn’t been available for long enough for anyone to actually read it.

This is the “reconciliation” bill, the first signature legislation moved by Republicans in Congress and President Trump. This bill has special rules that make it immune to the Senate filibuster, so it can pass the Senate if a simple majority vote for it.

Keep ReadingShow less
How Language and Cultural Barriers in Healthcare Plague Seattle’s Latino Community

stethoscope on top of a clipboard

Getty Images

How Language and Cultural Barriers in Healthcare Plague Seattle’s Latino Community

A visit to the hospital can already be a stressful event for many. For those in the Seattle Latino community, language and cultural barriers present in the healthcare system can make the process even more daunting.

According to Leo Morales, a healthcare provider at UW Medicine’s LatinX Diabetes Clinic and co-director of the Latino Center for Health, communication difficulties are one of the most obvious barriers in healthcare for Latinos with limited English proficiency.

Keep ReadingShow less